Zenith Epigenetics
  • About
  • Science & Epigenetics
  • Programs
  • Newsroom
  • Contact
  • Connect
    Email
    info@zenithepigenetics.com
    Call
    1 (587) 390-7865
    Share
  • FAQ
Newsroom
  • News Releases
  • Presentations & Events
  • SEDAR Filings

News Releases

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer
November 20, 2018
Zenith Epigenetics Announces Publication of Covalent Bromodomain Inhibitors, Offering a Novel Approach to Targeting BET Bromodomains
October 1, 2018
Zenith Announces Voting Results from the 2018 Annual Meeting of Shareholders
September 12, 2018
Zenith Epigenetics Announces Publication of a Case Study From its Ongoing mCRPC Clinical Study
September 4, 2018
Zenith Capital Closes $5.7 Million Private Placement
August 31, 2018
Zenith Announces Further Advancement of Clinical Trial with ZEN-3694, a Proposed Equity Offering and an Update Webcast
June 4, 2018

About

  • Overview
  • Management
  • Board of Directors

Science & Epigenetics

  • What is Epigenetics?
  • BET Inhibitors & Oncology
    • Resistance & Combo Therapy
  • BET Inhibitor Platform
    • Covalent BET Inhibitors
    • Translational Medicine
  • Publications & Posters

Programs

  • Oncology Pipeline
    • Prostate Cancer
    • Breast Cancer
    • Ovarian Cancer
    • Lung Cancer
    • Other Solid Tumor Cancers
  • Partnerships & Collaborations

Newsroom

  • News Releases
  • Presentations & Events
  • SEDAR Filings

Contact

  • Contact
  • Careers
  • Shareholder FAQ

© 2025 zenithepigenetics | Legal | Privacy

Bookmark and Share